Private Diagnostic Company Completes Sale of SPECT Business to Technology Firm

Lantheus Medical Incorporated (Lantheus) announced today that it has closed its previously disclosed sale of certain assets and liabilities related to its nuclear medicine business, including the company’s SPECT imaging portfolio, to SHINE Technologies. The transaction was completed in accordance with the terms agreed upon at the time of the initial announcement, with SHINE taking over full responsibility for the operation and development of Lantheus’ existing SPECT systems. This move marks a strategic shift for both parties, allowing Lantheus to focus on other areas of growth while providing a new opportunity for SHINE to expand its reach in the nuclear medicine market. The sale is expected to facilitate a smoother transition for customers and ensure minimal disruption to existing relationships. As part of this agreement, Lantheus will receive approximately $12 million in upfront cash consideration from SHINE, as well as potential future payments tied to the performance of certain metrics. SHINE Technologies has expressed its commitment to supporting the continued growth and development of nuclear medicine technology, and the acquisition is seen as a strategic move to bolster its offerings in this critical healthcare sector. With this transaction complete, Lantheus can now concentrate on further expanding its portfolio through strategic acquisitions and collaborations that align with the company’s long-term vision. The deal has been met with enthusiasm from industry observers, who note that the sale represents an opportunity for SHINE to accelerate its product development pipeline and enhance its market presence.